U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Poly (ADP-Ribose) polymerase inhibitor response

MedGen UID:
1003353
•Concept ID:
CN322715
•
Sign or Symptom
Synonym: PARP Inhibitor response
Drug:
Poly (ADP-ribose) polymerase (PARP) inhibitior
MedGen UID:
364201
•Concept ID:
C1882413
•
Pharmacologic Substance
Any substance that inhibits Poly (ADP-Ribose) polymerase, an enzyme involved in detecting DNA single strand breaks and the initiation of DNA repair. Inhibition of Poly (ADP-Ribose) polymerase has direct cytotoxic effects by inhibiting DNA repair and causing cell death. [from NCI]
Poly (ADP-ribose) polymerase (PARP) inhibitior

Professional guidelines

PubMed

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK
JCO Glob Oncol 2024 Jan;10:e2300285. doi: 10.1200/GO.23.00285. PMID: 38206277Free PMC Article
Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors.
Golan T, Raitses-Gurevich M, Beller T, Carroll J, Brody JR
Cancer Treat Res 2023;186:125-142. doi: 10.1007/978-3-031-30065-3_8. PMID: 37978134
Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Monk BJ, González-Martin A, Buckley L, Matulonis UA, Rimel BJ, Wu X, Moore KN, Mirza MR
Int J Gynecol Cancer 2023 Jun 5;33(6):971-981. doi: 10.1136/ijgc-2022-004079. PMID: 36792166Free PMC Article

Recent clinical studies

Etiology

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators
J Clin Oncol 2023 Jan 20;41(3):609-617. Epub 2022 Sep 9 doi: 10.1200/JCO.22.01549. PMID: 36082969Free PMC Article
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J
Cochrane Database Syst Rev 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PMID: 35170751Free PMC Article
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M
N Engl J Med 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28 doi: 10.1056/NEJMoa1911440. PMID: 32343890
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators
N Engl J Med 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. PMID: 31851799
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators
N Engl J Med 2019 Dec 19;381(25):2391-2402. Epub 2019 Sep 28 doi: 10.1056/NEJMoa1910962. PMID: 31562799

Diagnosis

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P; PAOLA-1/ENGOT-ov25 investigators
Ann Oncol 2023 Aug;34(8):681-692. Epub 2023 May 19 doi: 10.1016/j.annonc.2023.05.005. PMID: 37211045
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators
J Clin Oncol 2023 Jan 20;41(3):609-617. Epub 2022 Sep 9 doi: 10.1200/JCO.22.01549. PMID: 36082969Free PMC Article
PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev 2020 Mar 1;34(5-6):360-394. Epub 2020 Feb 6 doi: 10.1101/gad.334516.119. PMID: 32029455Free PMC Article
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators
N Engl J Med 2019 Dec 19;381(25):2391-2402. Epub 2019 Sep 28 doi: 10.1056/NEJMoa1910962. PMID: 31562799
Exploring and comparing adverse events between PARP inhibitors.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL
Lancet Oncol 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. PMID: 30614472Free PMC Article

Therapy

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL
J Clin Oncol 2023 May 1;41(13):2436-2445. Epub 2023 Jan 30 doi: 10.1200/JCO.22.01900. PMID: 36716407Free PMC Article
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators
J Clin Oncol 2023 Jan 20;41(3):609-617. Epub 2022 Sep 9 doi: 10.1200/JCO.22.01549. PMID: 36082969Free PMC Article
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M
N Engl J Med 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28 doi: 10.1056/NEJMoa1911440. PMID: 32343890
PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev 2020 Mar 1;34(5-6):360-394. Epub 2020 Feb 6 doi: 10.1101/gad.334516.119. PMID: 32029455Free PMC Article
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P
N Engl J Med 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4 doi: 10.1056/NEJMoa1706450. PMID: 28578601

Prognosis

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators
J Clin Oncol 2023 Jan 20;41(3):609-617. Epub 2022 Sep 9 doi: 10.1200/JCO.22.01549. PMID: 36082969Free PMC Article
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkilä J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E
Clin Cancer Res 2022 Nov 1;28(21):4724-4736. doi: 10.1158/1078-0432.CCR-22-0301. PMID: 35929986Free PMC Article
Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA, Spruck C
Int J Oncol 2020 Dec;57(6):1245-1261. Epub 2020 Oct 16 doi: 10.3892/ijo.2020.5135. PMID: 33174058Free PMC Article
PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev 2020 Mar 1;34(5-6):360-394. Epub 2020 Feb 6 doi: 10.1101/gad.334516.119. PMID: 32029455Free PMC Article
PARP Inhibitors in Ovarian Cancer.
Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G
Recent Pat Anticancer Drug Discov 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. PMID: 29512470

Clinical prediction guides

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators
J Clin Oncol 2023 Jan 20;41(3):609-617. Epub 2022 Sep 9 doi: 10.1200/JCO.22.01549. PMID: 36082969Free PMC Article
Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD
Mol Cell 2020 Jun 18;78(6):1070-1085. Epub 2020 May 26 doi: 10.1016/j.molcel.2020.04.035. PMID: 32459988Free PMC Article
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M
N Engl J Med 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28 doi: 10.1056/NEJMoa1911440. PMID: 32343890
PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev 2020 Mar 1;34(5-6):360-394. Epub 2020 Feb 6 doi: 10.1101/gad.334516.119. PMID: 32029455Free PMC Article
PARP Inhibitors in Ovarian Cancer.
Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G
Recent Pat Anticancer Drug Discov 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. PMID: 29512470

Recent systematic reviews

The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N, Ciliberto D, Luciano F, Napoli C, Costa M, Rossini G, Arbitrio M, Labanca C, Riillo C, Del Giudice T, Crispino A, Salvino A, Galvano A, Russo A, Tassone P, Tagliaferri P
Crit Rev Oncol Hematol 2024 Jan;193:104229. Epub 2023 Dec 7 doi: 10.1016/j.critrevonc.2023.104229. PMID: 38065404
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D
Cancer Treat Rev 2022 Dec;111:102468. Epub 2022 Sep 28 doi: 10.1016/j.ctrv.2022.102468. PMID: 36202026
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A
J Clin Oncol 2022 Sep 20;40(27):3205-3221. Epub 2022 Jun 27 doi: 10.1200/JCO.22.01063. PMID: 35759724
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J
Cochrane Database Syst Rev 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PMID: 35170751Free PMC Article
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...